Sanofi, Regeneron See Positive Results From Dupixent Phase 3 Trial
23 May 2020 - 9:34AM
Dow Jones News
By Kimberly Chin
Sanofi SA and Regeneron Pharmaceuticals Inc. said it had
positive results for an advanced trial of a treatment for patients
with a chronic, allergic inflammatory disease of the esophagus.
The Phase 3 trial of Dupixent met both its co-primary endpoints,
as well as important secondary endpoints, the companies said. The
trial had 81 patients, ages 12 years and older, who had
eosinophilic esophagitis.
The patients were able to show clinical and anatomic
improvements, including the ability to swallow. Patients saw a 69%
reduction in disease symptoms, as well as a 60% reduction in their
esophageal eosinophilic count to a normal range, the companies
said.
Eosinophilic esophagitis damages the esophagus and impairs its
functions, making it difficult to swallow. It could also damage and
scar the esophagus without treatment.
This was the first and only biologic to show "positive and
clinically meaningful results" in an advanced trial, the companies
said.
Write to Kimberly Chin at kimberly.chin@wsj.com
(END) Dow Jones Newswires
May 22, 2020 19:19 ET (23:19 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Jul 2023 to Jul 2024